Research Article
An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice
Asghar Abdoli,
Hoorieh Soleimanjahi,
Masoumeh Tavassoti Kheiri,
Abbas Jamali,
Vahideh Mazaheri,
Meghdad Abdollahpour Alitappeh,
Asghar Abdoli
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Search for more papers by this authorCorresponding Author
Hoorieh Soleimanjahi
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Correspondence
Hoorieh Soleimanjahi, Virology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Tel.: +(98) 21 82883561
fax: +(98) 21 82883581
e-mail: [email protected]
Search for more papers by this authorMasoumeh Tavassoti Kheiri
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorAbbas Jamali
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorVahideh Mazaheri
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorMeghdad Abdollahpour Alitappeh
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorAsghar Abdoli,
Hoorieh Soleimanjahi,
Masoumeh Tavassoti Kheiri,
Abbas Jamali,
Vahideh Mazaheri,
Meghdad Abdollahpour Alitappeh,
Asghar Abdoli
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Search for more papers by this authorCorresponding Author
Hoorieh Soleimanjahi
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Correspondence
Hoorieh Soleimanjahi, Virology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Tel.: +(98) 21 82883561
fax: +(98) 21 82883581
e-mail: [email protected]
Search for more papers by this authorMasoumeh Tavassoti Kheiri
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorAbbas Jamali
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorVahideh Mazaheri
Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorMeghdad Abdollahpour Alitappeh
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Search for more papers by this authorThis article reports some interesting results obtained immunizing mice against influenza using chimeric virosomes, furthering the advancement of virosome technology. Virosomes could become attractive system to vaccinate using multiple epitopes, providing broad protection against pathogens that have multiple serotypes or are highly mutagenic.
Abstract
Annual health threats and economic damages caused by influenza virus are still a main concern of the World Health Organization and other health departments all over the world. An influenza virosome is a highly efficient immunomodulating carrier mimicking the natural antigen presentation pathway and has shown an excellent tolerability profile due to its biocompatibility and purity. The major purpose of this study was to construct a new chimeric virosome influenza vaccine containing hemagglutinin (HA) and neuraminidase (NA) proteins derived from the A/PR/8/1934 (H1N1) (PR8) and A/X/47 (H3N2) (X47) viruses, and to evaluate its efficacy as a vaccine candidate in mice. A single intramuscular vaccination with the chimeric virosomes provided complete protection against lethal challenge with the PR8 and X47 viruses. The chimeric virosomes induced high IgG antibody responses as well as hemagglutination inhibition (HAI) titers. HAI titers following the chimeric virosome vaccination were at the same level as the whole inactivated influenza vaccine. Mice immunized with the chimeric virosomes displayed considerably less weight loss and exhibited significantly reduced viral load in their lungs compared with the controls. The chimeric virosomes can be used as an innovative vaccine formulation to confer protection against a broad range of influenza viruses.
References
- Abdoli A, Soleimanjahi H, Kheiri MT, Jamali A & Jamaati A (2013a) Determining influenza virus shedding at different time points in Madin-Darby canine kidney cell line. Cell J 15: 130–135.
- Abdoli A, Soleimanjahi H, Kheiri MT, Sohani MH, Abdoli M & Rahmatollahi H (2013b) Reconstruction of H3N2 influenza virus based virosome in vitro. Iran J Microbiol 5: 166–171.
- Almeida J, Edwards DC, Brand C & Heath T (1975) Formation of virosomes from influenza subunits and liposomes. Lancet 306: 899–901.
10.1016/S0140-6736(75)92130-3 Google Scholar
- Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A & Zurbriggen R (2005) Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol 17: 695–704.
- Anvar E, Hosseini SM, Kheiri MT et al. (2013) Serological survey of avian influenza (H9N2) among different occupational groups in Tehran and Qazvin Provinces in IR Iran. Jundishapur J Microbiol 6: 1–4.
- Bock A, Schulze-Horsel J, Schwarzer J, Rapp E, Genzel Y & Reichl U (2011) High-density microcarrier cell cultures for influenza virus production. Biotechnol Prog 27: 241–250.
- Bovier PA (2008) Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 7: 1141–1150.
- Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T & Machy P (2002) Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20: 2287–2295.
- Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J & Daemen T (2005) Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23: 1232–1241.
- D'Acremont V, Herzog C & Genton B (2006) Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in the elderly. J Travel Med 13: 78–83.
- Daniels R, Downie J, Hay A, Knossow M, Skehel J, Wang M & Wiley D (1985) Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 40: 431–439.
- De Bruijn I, Nauta J, Gerez L & Palache A (2004) Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 103: 139–145.
- De Bruijn I, Nauta J, Gerez L & Palache A (2006) The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 24: 6629–6631.
- Felnerova D, Viret J-F, Glück R & Moser C (2004) Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15: 518–529.
- Genzel Y, Behrendt I, König S, Sann H & Reichl U (2004) Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 22: 2202–2208.
- Ghanbari Safari M & Hosseinkhani S (2013) Lipid composition of cationic nanoliposomes implicate on transfection efficiency. J Liposome Res 23: 174–186.
- Glück R, Mischler R, Brantschen S, Just M, Althaus B & Cryz S Jr (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90: 2491–2495.
- Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR & Schiffman D (1977) A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 136: 623–632.
- Gruber WC, Belshe RB, King JC et al. (1996) Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 173: 1313–1319.
- Hagenaars N, Mastrobattista E, Glansbeek H et al. (2008) Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26: 6555–6563.
- Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X & Mokhtari-Azad T (2012) Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS ONE 7: 1–11.
- Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H & Glück R (2009) Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine 27: 4381–4387.
- Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM & Wilschut J (2005) The virosome concept for influenza vaccines. Vaccine 23: 26–38.
- Huckriede A, De Jonge J, Holtrop M & Wilschut J (2007) Cellular delivery of siRNA mediated by fusion-active virosomes. J Liposome Res 17: 39–47.
- Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F & Kheiri MT (2010) A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Clin Vaccine Immunol 17: 683–687.
- Jamali A, Holtrop M, de Haan A et al. (2012) Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett 148: 77–82.
- Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A & Di Pietrantonj C (2005) Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 365: 773–780.
- de Jonge J, Holtrop M, Wilschut J & Huckriede A (2005) Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 13: 400–411.
- de Jonge J, Schoen P, terVeer W, Stegmann T, Wilschut J & Huckriede A (2006) Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim Biophys Acta 1758: 527–536.
- Kanra G, Marchisio P, Feiterna-Sperling C et al. (2004) Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23: 300–306.
- Kapoor D, Vyas R, Lad C & Patel M (2013) A multipurpose and novel carrier for drug delivery and targeting-virosomes. J Drug Deliv Therapeut 3: 143–147.
- Kheiri MT, Jamali A, Shenagari M, Hashemi H, Sabahi F, Atyabi F & Saghiri R (2012) Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antivir Res 95: 229–236.
- Kistner O, Barrett P, Mundt W, Reiter M, Schober-Bendixen S & Dorner F (1998) Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16: 960–968.
- Kumar M, Nandi S & Chidri S (2010) Development of a polyclonal antibody-based AC-ELISA and its comparison with PCR for diagnosis of canine parvovirus infection. Virol Sin 25: 352–360.
- Lamb R & Krug R (2001) Fields virology, 4th edn: ch. 46: Orthomyxoviridae: The Viruses and Their Replication ( BN Fields, DM Knipe & PM Howley eds), pp. 1487–1531. Lippincott, Williams and Wilkins: Philadelphia, PA.
- Lee BW, Bey RF, Baarsch MJ & Simonson RR (1993) ELISA method for detection of influenza A infection in swine. J Vet Diagn Invest 5: 510–515.
- Liu X, Siegrist S, Amacker M, Zurbriggen R, Pluschke G & Seeberger PH (2006) Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol 1: 161–164.
- Lowry O, Rosebrough N, Farr A & Randall R (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
- Mallick AI, Parvizi P, Read LR, Nagy É, Behboudi S & Sharif S (2011) Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 29: 1657–1665.
- Mischler R & Metcalfe IC (2002) Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20: 17–23.
- Moser C & Amacker M (2013) Influenza virosomes as antigen delivery system. Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines, 1st edn. ( M Singh, Ed), pp. 287–307. Springer, New York.
10.1007/978-1-4614-5380-2_14 Google Scholar
- Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N & Zurbriggen R (2007) Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 6: 711–721.
- Moser C, Amacker M & Zurbriggen R (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10: 437–446.
- Moser C, Müller M, Kaeser MD, Weydemann U & Amacker M (2013) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 12: 779–791.
- Noori M, Ghorbani S, Jamali A et al. (2012) Construction of Influenza A/H1N1 virosomal nanobioparticles. Iran J Virol 5: 13–18.
- Quan F-S, Vunnava A, Compans RW & Kang S-M (2010) Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS ONE 5: 1–10.
- Rezaei F, Mirshafiey A, Shahmahmoodi S, Shoja Z, Ghavami N & Mokhtari-Azad T (2013) Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses. Iran Red Crescent Med J 15: 75–82.
- Samdal HH, Bakke H, Oftung F et al. (2005) A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Human Vaccines 1: 85–90.
- Shafique M, Meijerhof T, Wilschut J & de Haan A (2013) Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS ONE 8: 1–12.
- Sharma R & Yasir M (2010) Virosomes: a novel carrier for drug delivery. Int J Pharm Tech Res 2: 2327–2339.
- Shaw ML, Stone KL, Colangelo CM, Gulcicek EE & Palese P (2008) Cellular proteins in influenza virus particles. PLoS Pathog 4: 1–13.
- Skehel JJ & Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann Rev Biochem 69: 531–569.
- Stegmann T, Morselt H, Booy F, van Breemen JFL, Scherphof G & Wilschut J (1987) Functional reconstitution of influenza virus envelopes. EMBO J 6: 2651–2659.
- Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A & Wilschut J (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 28: 5543–5550.
- Tanzi E, Esposito S, Bojanin J et al. (2006) Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 78: 440–445.
- Thompson FM, Porter DW, Okitsu SL et al. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3: 1–13.
- Weis W, Brown J, Cusack S, Paulson J, Skehel J & Wiley D (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333: 426–431.
- Wiedermann U, Wiltschke C, Jasinska J et al. (2010) A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treatment 119: 673–683.
- Wilschut J (2009) Influenza vaccines: the virosome concept. Immunol Lett 122: 118–121.
- Yousefi A, Fotouhi F, Hosseinzadeh S, Kheiri M, Farahmand B, Montazeri S & Mousavi F (2012) Expression of antigenic determinants of the haemagglutinin large subunit of novel influenza virus in insect cells. Folia Biol (Praha) 58: 151–156.
- Zandi K, Roostaee MH, Sadeghizadeh M, Rasaee MJ, Sajedi RH & Soleimanjahi H (2007) Production of recombinant gG-1 protein of herpes simplex virus type 1 in a prokaryotic system in order to develop a type-specific enzyme-linked immunosorbent assay kit. FEMS Immunol Med Microbiol 50: 319–323.
- Zurbriggen R & Glück R (1999) Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17: 1301–1305.
